Synapse - Steven Horwitz

Search Within

Steven M Horwitz

Results (671)

Adult T-cell leukemia/lymphoma

Journal Article

Mehta-Shah, N.; Ratner, L.; Horwitz, S. M.
Journal of Oncology Practice (2017)

The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma

Journal Article

Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
Clinical Cancer Research (2017)

Fulltext@MSK | Save

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial

Journal Article

Prince, H. M.; Kim, Y. H.; Horwitz, S. M.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Sanches, J. A.; Ortiz-Romero, P. L.; more...
Lancet (2017)

Fulltext@MSK | Save

Phase 3 ALCANZA study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (Bex) in CD30-positive cutaneous T-cell lymphoma (CTCL): Number needed to treat analysis

Meeting Abstract

Zagadailov, E.; Prince, H. M.; Whittaker, S.; Horwitz, S.; Duvic, M.; Kim, Y.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P. L.; more...
Haematologica (2017)

Fulltext@MSK | Save

Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma

Journal Article

Duvic, M.; Kim, Y. H.; Zinzani, P. L.; Horwitz, S. M.
Clinical Cancer Research (2017)

Fulltext@MSK | Save

Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: Analysis of two phase II trials

Journal Article

Shustov, A.; Coiffier, B.; Horwitz, S.; Sokol, L.; Pro, B.; Wolfson, J.; Balser, B.; Eisch, R.; Popplewell, L.; Prince, H. M.; more...
Leukemia and Lymphoma (2017)

Fulltext@MSK | Save

Interim data from the first clinical study of ADCT-301, a novel pyrrolobenzodiazapine-based antibody drug conjugate, in relapsed/refractory Hodgkin/non-Hodgkin lymphoma

Meeting Abstract

Horwitz, S. M.; Fanale, M. A.; Spira, A. I.; Havenith, K.; He, S.; Feingold, J. M.; Hamadani, M.
Hematological Oncology (2017)

Fulltext@MSK | Save

Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell non-Hodgkin lymphoma: Phase I results from the T-cell consortium

Meeting Abstract

Lunning, M.; Horwitz, S.; Mehta-Shah, N.; Moskowitz, A.; Advani, R.; Beaven, A.; Haverkos, B.; Lechowicz, M.; Oki, Y.; Zain, J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study

Meeting Abstract

Horwitz, S.; Whittaker, S.; Duvic, M.; Dummer, R.; Kim, Y. H.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Eradat, H.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: Results from the Phase 3 ALCANZA study

Meeting Abstract

Prince, H. M.; Dummer, R.; Whittaker, S.; Horwitz, S.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Sanches, J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save